Lineaue determination of CD20-B-cell neoplasms: An inummohistochemical study
Lineaue determination of CD20-B-cell neoplasms: An inummohistochemical study
复制标题
DOI：
10.1309/3wg32yramq7rb9d4
复制
发表时间：
2006-10-01
影响因子：
3.5
通讯作者：
Weiss, Lawrence M.
中科院分区：
文献类型：
--
作者：
Chu, Peiguo G.;Loera, Sofia;Weiss, Lawrence M.
我们研究了61例CD 20-B细胞淋巴瘤，包括29例前体B细胞淋巴母细胞白血病、淋巴母细胞淋巴瘤（B-ALL/B-LBL）、25例利妥昔单抗治疗后复发的CD 20-成熟B细胞淋巴瘤和7例CD 20-弥漫性大B细胞淋巴瘤（DLBCL）。我们使用了对B谱系特异的标志物：CD 79 a、Pax-5、OCT. 2和BOB. 1。所有B-ALL/B-LBL均表达Pax-5（29/29 [100%]），27例中有25例（93%）表达BOB.1，29例中有23例（79%）表达CD 79 a，27例中有6例（22%）表达OCT. 2。在利妥昔单抗治疗后CD 20复发的成熟B细胞淋巴瘤中，表达Pax-5、CD 79 a、OCT. 2和BOB. 1的病例百分比分别为88%（21/24）、84%（21/25）、81%（17/21）和73%（16/22）。CD 20-DLBCL很少表达常规B系标志物，如CD 79 a和Pax-5，但它们表达OCT. 2或BOB. 1。Pax-5、BOB.1和CD 79 a抗原是B-ALL/B-LBL石蜡免疫分型最可靠的B系标志物。CD 79 a和Pax-5应作为利妥昔单抗治疗的CD 20成熟B细胞淋巴瘤的一线B谱系特异性标志物。如果为阴性，则为10月2日或BOB。我可能有用。新发现的B系标志物OCT 2和BOB.1可能是最适用于确定CD 20-血浆白蛋白或DLBCL原发性渗出亚型的B系。
We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia,lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20-recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20-diffuse large B cell lymphoma (DLBCL). We used markers specific for B lineage: CD79a, Pax-5, OCT.2, and BOB.1. All B-ALL/B-LBLs expressed Pax-5 (29/29 [100%]), 25 (93%) of 27 expressed BOB.1, 23 (79%) of 29 expressed CD79a, and 6 (22%) of 27 expressed OCT.2. The percentages of cases expressing Pax-5, CD79a, OCT.2, and BOB.1 in CD20- recurrent mature B-cell lymphomas after rituximab treatment were 88% (21/24), 84% (21/25), 81% (17/21), and 73% (16/22), respectively. CD20- DLBCLs rarely express routine B-lineage markers, such as CD79a and Pax-5, but they expressed OCT.2 or BOB.1. Pax-5, BOB.1, and CD79a antigens are the most reliable B-lineage markers for paraffin immunophenotyping B-ALL/B-LBL. CD79a and Pax-5 should be used as the first-line B lineage-specific markers for rituximab-treated CD20-mature B-cell lymphomas. If negative, OCT.2 or BOB. I may be useful. The newly identified B-lineage markers, OCT 2 and BOB.1, may be the most useful for the B-lineage determination of CD20-plasmablastic or primary effusion subtypes of DLBCL.